betadex and Keratoconus

betadex has been researched along with Keratoconus* in 1 studies

Other Studies

1 other study(ies) available for betadex and Keratoconus

Article	Year
Design, Optimization, and Characterization of Lactoferrin-Loaded Chitosan/TPP and Chitosan/Sulfobutylether-β-cyclodextrin Nanoparticles as a Pharmacological Alternative for Keratoconus Treatment. ACS applied materials & interfaces, 2021, Jan-27, Volume: 13, Issue:3 This research study describes the design, optimization, and characterization of two different types of chitosan-based nanoparticles as novel drug delivery systems of a protein drug, lactoferrin. A preclinical consistent base was obtained for both nanosystems, being considered as the first pharmacological treatment for keratoconus as an alternative to current invasive clinical methods. Both types of nanoparticles were obtained via the ionotropic gelation technique. The size and morphology of the nanoparticles were studied as a function of the preparation conditions. A mean size of 180.73 ± 40.67 nm, a size distribution [polydispersity index (PDI)] of 0.170 ± 0.067, and positive ζ-potential values, ranging from 17.13 to 19.89 mV, were achieved. Lactoferrin was successfully incorporated into both types of nanocarriers. Topics: Animals; Anti-Infective Agents; beta-Cyclodextrins; Cattle; Chickens; Chitosan; Cornea; Delayed-Action Preparations; Drug Delivery Systems; Humans; Keratoconus; Lactoferrin; Male; Nanoparticles; Rats, Sprague-Dawley	2021

Article

Year

Design, Optimization, and Characterization of Lactoferrin-Loaded Chitosan/TPP and Chitosan/Sulfobutylether-β-cyclodextrin Nanoparticles as a Pharmacological Alternative for Keratoconus Treatment.

ACS applied materials & interfaces, 2021, Jan-27, Volume: 13, Issue:3

This research study describes the design, optimization, and characterization of two different types of chitosan-based nanoparticles as novel drug delivery systems of a protein drug, lactoferrin. A preclinical consistent base was obtained for both nanosystems, being considered as the first pharmacological treatment for keratoconus as an alternative to current invasive clinical methods. Both types of nanoparticles were obtained via the ionotropic gelation technique. The size and morphology of the nanoparticles were studied as a function of the preparation conditions. A mean size of 180.73 ± 40.67 nm, a size distribution [polydispersity index (PDI)] of 0.170 ± 0.067, and positive ζ-potential values, ranging from 17.13 to 19.89 mV, were achieved. Lactoferrin was successfully incorporated into both types of nanocarriers.

Topics: Animals; Anti-Infective Agents; beta-Cyclodextrins; Cattle; Chickens; Chitosan; Cornea; Delayed-Action Preparations; Drug Delivery Systems; Humans; Keratoconus; Lactoferrin; Male; Nanoparticles; Rats, Sprague-Dawley

2021